biosimilars

Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster
Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster
Pharmaforum
Amgen
Allergan
biosimilars
Roche
rituximab
Flag link:
Biosimilar sales to reach $6.5B by 2024, study says
Biosimilar sales to reach $6.5B by 2024, study says
Beckers Hospital Review
biosimilars
Flag link:
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Flag link:
Is Merck a Better Buy After Announcing Spinoff?
Is Merck a Better Buy After Announcing Spinoff?
Motley Fool
Merck
spinoffs
Women's Health
biosimilars
Flag link:
Lilly, Novo Nordisk Fight Insulin Biosimilars With Tweaks to FDA Draft Guidance
Lilly, Novo Nordisk Fight Insulin Biosimilars With Tweaks to FDA Draft Guidance
RAPS.org
diabetes
insulin
biosimilars
Eli Lilly
Novo Nordisk
FDA
competition
Flag link:
Bio-Thera Solutions announces positive top-line results for BAT1706, a proposed biosimilar to Avastin
Bio-Thera Solutions announces positive top-line results for BAT1706, a proposed biosimilar to Avastin
Pharmaceutical Business Review
BAT1706
Bio-Thera Solutions
Avastin
Roche
non-squamous non-small cell lung cancer
biosimilars
Flag link:
The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers
The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers
Motley Fool
FDA
FTC
drug pricing
anti-competitive scheme
biosimilars
Flag link:
Amgen, Pfizer biosimilar sales pressure top drugs
Amgen, Pfizer biosimilar sales pressure top drugs
BioPharma Dive
biosimilars
Amgen
Pfizer
Roche
Flag link:
Roche fights off biosimilar competition as new medicines' sales soar
Roche fights off biosimilar competition as new medicines' sales soar
Pharmaforum
Roche
biosimilars
earnings
Flag link:
5 years of biosimilars in the US: what have we learned?
5 years of biosimilars in the US: what have we learned?
Pharmaforum
biosimilars
cancer
autoimmune disease
Flag link:
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in US
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in US
Pharmaforum
Pfizer
Roche
biosimilars
Avastin
Zirabev
Herceptin
Trazimera
Rituxan
Ruxience
Flag link:
Fighting for market share, J&J expects last year's copycat pain to 'bleed into 2020'
Fighting for market share, J&J expects last year's copycat pain to 'bleed into 2020'
Fierce Pharma
JNJ
biosimilars
Velcade
Zytiga
patents
Flag link:
Celltrion plans to launch a biosimilar each year for next decade
Celltrion plans to launch a biosimilar each year for next decade
Pharmaforum
Celltrion
South Korea
biosimilars
JPMHC 2020
Flag link:
Innovent and Coherus Strike Licensing Agreement for Avastin Biosimilar
Innovent and Coherus Strike Licensing Agreement for Avastin Biosimilar
BioSpace
China
Innovent Biologics
Coherus Biosciences
biosimilars
Avastin
Flag link:
WHO Prequalifies its First Biosimilar
WHO Prequalifies its First Biosimilar
RAPS.org
WHO
biosimilars
Samsung Bioepis
Ontruzant
Roche
Herceptin
breast cancer
Flag link:
The 4 biggest pharma market access stories of 2019
The 4 biggest pharma market access stories of 2019
Pharmaforum
biosimilars
UK
Orkambi
Vertex Pharmaceuticals
drug pricing
FDA
NICE
Flag link:
FDA takes another step to encourage copycat insulin products
FDA takes another step to encourage copycat insulin products
Pharmaforum
FDA
diabetes
insulin
biosimilars
Flag link:
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
Fierce Pharma
Roche
breast cancer
Herceptin
Perjeta
biosimilars
SABCS
Flag link:
US biosimilar launches about to turn a corner
US biosimilar launches about to turn a corner
Endpoints
biosimilars
Europe
Flag link:
UCB posts more supportive data from Humira rival bimekizumab
UCB posts more supportive data from Humira rival bimekizumab
Pharmaforum
UCB Pharma
bimekizumab
AbbVie
Humira
psoriasis
biosimilars
Flag link:

Pages